Navigation Links
Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes
Date:3/4/2009

The 2009 Walk to Cure Diabetes will be held Saturday, October 17 at

Centennial Olympic Park

ATLANTA, March 4 /PRNewswire/ -- The Georgia Chapter of the Juvenile Diabetes Research Foundation (JDRF) has announced that Blue Cross and Blue Shield of Georgia (BCBSGa) President, Monye Connolly, will serve as the Corporate Chair for its annual, and largest, fundraising event, Walk to Cure Diabetes. The event is scheduled in Atlanta at Centennial Olympic Park on Saturday, Oct. 17, 2009.

Last year's walk raised more than $1.5 million to fund research to help find a cure for diabetes.

"The Juvenile Diabetes Research Foundation is firm in its commitment to finding a cure for diabetes and its complications through the support of research. BCBSGa truly believes in JDRF and its mission, which supports our mission of improving the lives of the people we serve and the health of our communities," said Connolly.

"We look forward to working with Monye Connolly in the months to come to make the 2009 Walk our best one ever. As someone with type 1 diabetes myself, it is very gratifying to have the support of such a large, successful company in our relentless goal to find a cure for diabetes and its complications," said Kris Bagwell, JDRF Georgia Board President

As many as 3 million people in the U.S. are now living with type 1 diabetes. Each year more than 15,000 children are diagnosed with diabetes - that's 40 children per day. More than 85 percent of JDRF's expenditures directly support research and research-related education.

Corporate sponsorships, corporate Walk Teams and Family Walk Teams will be the key to the success of the Walk to Cure Diabetes. For more information about JDRF, the critical research they fund and how you can help, call 404-420-5990, or visit www.jdrf.org.

About JDRF:

JDRF was founded in 1970 by the parents of children with type-1 diabetes - a disease that strikes children, adolescents and adults suddenly, making them insulin dependent for life, which carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1.3 billion to diabetes research worldwide. More than 85 percent of JDRF's expenditures directly support research and research-related education. JDRF's mission is constant: to find a cure for diabetes and its complications through the support of research. To register now and participate, sponsor an event, build a walk team, or for more information, please visit www.jdrf.org, or call 404-420-5990.

About Blue Cross Blue Shield of Georgia:

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross and Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross and Blue Shield Association(R) . The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Additional information about Blue Cross and Blue Shield of Georgia is available at www.bcbsga.com.


'/>"/>
SOURCE Juvenile Diabetes Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvanians May Donate Part of Tax Refund to Support Juvenile Diabetes Research
2. Etanercept, Methotrexate Safe for Juvenile RA
3. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
4. University of South Florida receives new multimillion award to assess juvenile diabetes treatments
5. Drug May Ease Symptoms of Juvenile Arthritis
6. Pediatric researchers find possible master switch gene in juvenile arthritis
7. Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis
8. Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis
9. Chrysler LLC Vice Chairman and President Jim Press and His Wife Suwichada Serve as Honorary Co-Chairs of Annual Juvenile Diabetes Research Foundation Promise Ball
10. Study affirms effectiveness of medication for juvenile rheumatoid arthritis
11. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: